Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (878 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
A nonspecific tumor-like inflammatory lesion in the orbit of the eye. It is usually composed of mature lymphocytes; plasma cells; macrophages; leukocytes with varying degrees of fibrosis. Orbital pseudotumors are often associated with inflammation of the extraocular muscles (orbital myositis) or inflammation of the lacrimal glands (dacryoadenitis).
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Orbital Pseudotumors; Pseudotumor, Orbital; Pseudotumors, Orbital; Inflammatory Pseudotumor of Orbit; Inflammatory Pseudotumor, Orbital; Inflammatory Pseudotumors, Orbital; Orbital Inflammatory Pseudotumors; Pseudotumor, Orbital Inflammatory.
Where it fits in the MeSH classification
- Broader topics
- Orbital Diseases
Related concepts
- Orbit
- Lymphocytes
- Plasma Cells
- Macrophages
- Leukocytes
- Fibrosis
- Orbital Myositis
- Dacryoadenitis
Research landscape
PubMed indexes 729 records tagged with the MeSH heading “Orbital Pseudotumor” (counts retrieved 2026-11-04). 100 of them (13.7%) were published from 2020 onward, and the busiest period so far is 2000-2009 with 249 records.
Reviews account for 115 records (15.8%) and meta-analyses for 1. Randomized controlled trials number 1 (0.1%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 134 |
| 2000-2009 | 249 |
| 2010-2019 | 246 |
| 2020 onward | 100 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 115 | 15.8% |
| Meta-analyses | 1 | 0.1% |
| Randomized controlled trials | 1 | 0.1% |
Method: PubMed query "Orbital Pseudotumor"[MeSH Terms] with publication-type and date filters, retrieved 2026-11-04.
Reading the evidence in eye, ear, nose and throat
Eye, hearing, nose and throat studies rely on specialist tests (visual acuity, eye pressure, audiograms, scopes) and on patient-reported symptoms, which vary between people and with age. Some conditions improve without treatment, so comparison groups matter. Nothing on this page is advice about diagnosis or treatment; sudden loss of sight or hearing needs urgent care from a qualified clinician. Check how the outcome was tested, the age of the people studied and how long they were followed.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Differentiation of orbital lymphoma and idiopathic orbital inflammatory pseudotumor: combined diagnostic value of conventional MRI and histogram analysis of ADC maps | 2018 | Research article Design not recorded in structured metadata | 46 | cc by PMID 29716527 · DOI · PMC5930683 |
| Orbital inflammatory pseudotumor: new advances in diagnosis, pathogenesis, and treatment | 2023 | Review article Design not recorded in structured metadata | 23 | cc by PMID 37794419 · DOI · PMC10548690 |
| IgG4-related disease in patients with idiopathic orbital inflammation | 2021 | Research article Design not recorded in structured metadata | 15 | cc by PMID 34625052 · DOI · PMC8499436 |
| Successful treatment of anti-neutrophil cytoplasmic antibody-associated inflammatory pseudotumour with rituximab: A case report | 2025 | Research article Design not recorded in structured metadata | 0 | cc by PMID 41054076 · DOI · PMC12499677 |
Differentiation of orbital lymphoma and idiopathic orbital inflammatory pseudotumor: combined diagnostic value of conventional MRI and histogram analysis of ADC maps [1]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundThe overlap of morphological feature and mean ADC value restricted clinical application of MRI in the differential diagnosis of orbital lymphoma and idiopathic orbital inflammatory pseudotumor (IOIP).
- Closing excerpt
- ConclusionsConventional MRI feature of involvement of orbit preseptal space and ADC histogram parameter of ADC10 are valuable in differential diagnosis of orbital lymphoma and IOIP.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (246 words)
BackgroundThe overlap of morphological feature and mean ADC value restricted clinical application of MRI in the differential diagnosis of orbital lymphoma and idiopathic orbital inflammatory pseudotumor (IOIP). In this paper, we aimed to retrospectively evaluate the combined diagnostic value of conventional magnetic resonance imaging (MRI) and whole-tumor histogram analysis of apparent diffusion coefficient (ADC) maps in the differentiation of the two lesions.MethodsIn total, 18 patients with orbital lymphoma and 22 patients with IOIP were included, who underwent both conventional MRI and diffusion weighted imaging before treatment. Conventional MRI features and histogram parameters derived from ADC maps, including mean ADC (ADCmean), median ADC (ADCmedian), skewness, kurtosis, 10th, 25th, 75th and 90th percentiles of ADC (ADC10, ADC25, ADC75, ADC90) were evaluated and compared between orbital lymphoma and IOIP. Multivariate logistic regression analysis was used to identify the most valuable variables for discriminating. Differential model was built upon the selected variables and receiver operating characteristic (ROC) analysis was also performed to determine the differential ability of the model.ResultsMultivariate logistic regression showed ADC10 (P = 0.023) and involvement of orbit preseptal space (P = 0.029) were the most promising indexes in the discrimination of orbital lymphoma and IOIP. The logistic model defined by ADC10 and involvement of orbit preseptal space was built, which achieved an AUC of 0.939, with sensitivity of 77.30% and specificity of 94.40%.ConclusionsConventional MRI feature of involvement of orbit preseptal space and ADC histogram parameter of ADC10 are valuable in differential diagnosis of orbital lymphoma and IOIP.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 29716527 · DOI · PMC5930683
Orbital inflammatory pseudotumor: new advances in diagnosis, pathogenesis, and treatment [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Orbital inflammatory pseudotumor (OIP) is a benign, non-specific inflammatory disorder that commonly occurs in middle-aged adults and is usually unilateral but can occur bilaterally.
- Closing excerpt
- Further exploration of the mechanism and signaling pathway of T cells in the immune process will help to identify their therapeutic targets and carry out targeted therapy to treat refractory OIP and reduce the side effects of traditional treatments.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (197 words)
Orbital inflammatory pseudotumor (OIP) is a benign, non-specific inflammatory disorder that commonly occurs in middle-aged adults and is usually unilateral but can occur bilaterally. Its clinical manifestations have tremendous clinical heterogeneity and vary according to the site of infiltration and the degree of lesions, including orbital pain, swelling, diplopia, proptosis, restricted eye movement, and decreased visual acuity. Clinical features, Image characteristics and pathological examinations often need to be evaluated to confirm the diagnosis. Currently, there is no systematic research on the pathogenesis of OIP, which may be related to immunity or infection. The first-line treatment is glucocorticoids. Radiotherapy, immunosuppressants, and biologics can be considered for treatment-resistant, hormone-dependent, or intolerant patients. In this review, we aim to summarize and focus on new insights into OIP, including new diagnostic criteria, pathogenesis, and discoveries in new drugs and treatment strategies. In particular, we highlight the literature and find that T cell-mediated immune responses are closely related to the pathogenesis of OIP. Further exploration of the mechanism and signaling pathway of T cells in the immune process will help to identify their therapeutic targets and carry out targeted therapy to treat refractory OIP and reduce the side effects of traditional treatments.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 37794419 · DOI · PMC10548690
IgG4-related disease in patients with idiopathic orbital inflammation [3]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundTo identify the prevalence of positive IgG4 immunostaining in orbital tissue among patients previously diagnosed with nongranulomatous idiopathic orbital inflammation (IOI) and to compare the clinical characteristics of patients with and without IgG4-positive cells.
- Closing excerpt
- Immunohistochemistry studies of all histopathology slides showing nongranulomatous IOI are highly recommended to evaluate for IgG4-RD.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (199 words)
BackgroundTo identify the prevalence of positive IgG4 immunostaining in orbital tissue among patients previously diagnosed with nongranulomatous idiopathic orbital inflammation (IOI) and to compare the clinical characteristics of patients with and without IgG4-positive cells.MethodsA retrospective review of all patients with a histopathologic diagnosis of IOI was performed. Immunohistochemical staining was performed to identify IgG-positive cells and IgG4-positive cells. Multivariate analysis was performed using likelihood ratio-test logistic regression on the differences between IgG4-related disease (IgG4-RD) and non-IgG4-RD.ResultsOf the 45 patients included, 21 patients (46.7%) had IgG4-positive cells, with 52.4% being male and a mean age of 55.9 ± 13.4 years. Bilateral ocular adnexal involvement (adjusted odds ratio [aOR] = 9.45; P = 0.016) and infraorbital nerve enlargement (aOR = 12.11; P = 0.008) were frequently found in IgG4-RD patients. Complete remission occurred in 23.8% of IgG4-RD patients and 41.7% of non-IgG4-RD patients. IgG4-RD patients had more frequent recurrent disease than non-IgG4-RD patients.ConclusionsNearly 50% of IgG4-RD patients were previously diagnosed with biopsy-proven IOI. IgG4-RD was more frequent in patients with bilateral disease and infraorbital nerve enlargement, showing the importance of tissue biopsy in these patients. Immunohistochemistry studies of all histopathology slides showing nongranulomatous IOI are highly recommended to evaluate for IgG4-RD.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 34625052 · DOI · PMC8499436
Successful treatment of anti-neutrophil cytoplasmic antibody-associated inflammatory pseudotumour with rituximab: A case report [4]
Abstract reading summary — source excerpts
- Opening excerpt
- RationaleAnti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare autoimmune condition that can involve various organ systems.
- Closing excerpt
- Early recognition and individualized immunosuppressive therapy are essential for preserving vision and improving outcomes in ocular ANCA-associated vasculitis.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (236 words)
RationaleAnti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare autoimmune condition that can involve various organ systems. Ocular involvement, though uncommon, may present as the initial or even sole manifestation. Orbital inflammatory pseudotumor, particularly its sclerosing subtype, can pose significant diagnostic and therapeutic challenges due to its steroid dependence and potential for recurrence.Patient concernsA 72-year-old Chinese man presented with a 6-month history of recurrent headaches. He later developed bilateral exophthalmos and progressive vision loss despite initial treatment. His past medical history included type 2 diabetes mellitus.DiagnosesThe patient initially tested positive for both p-ANCA and c-ANCA, with markedly elevated anti-myeloperoxidase and proteinase 3 antibody levels. Imaging revealed bilateral orbital masses consistent with orbital inflammatory pseudotumor, and biopsy confirmed sclerosing orbital inflammatory pseudotumor. Despite serological remission, clinical symptoms worsened during steroid tapering, suggesting steroid dependence.InterventionsThe patient was initially treated with high-dose corticosteroids and oral cyclophosphamide. Although symptoms improved transiently, relapse occurred upon tapering steroids. Rituximab (RTX; 500 mg weekly for 4 weeks) was then administered as second-line therapy.OutcomeThe patient experienced significant improvement following RTX therapy, which allowed successful steroid tapering. No further relapse occurred during short-term follow-up.LessonsThis case illustrates the limitations of cyclophosphamide-based regimens in managing steroid-dependent ANCA-associated orbital disease. RTX may be a more effective alternative in relapsing or refractory cases, particularly when ocular symptoms persist despite ANCA seronegativity. Early recognition and individualized immunosuppressive therapy are essential for preserving vision and improving outcomes in ocular ANCA-associated vasculitis.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41054076 · DOI · PMC12499677
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article What is orbital pseudotumor? [5]
- Research article Diagnostic criteria for IgG4-related ophthalmic disease [6]
- Research article Diagnosis and management of orbital pseudotumor [7]
- Research article IgG4-related systemic disease as a cause of "idiopathic" orbital inflammation, including orbital myositis, and trigeminal nerve involvement [8]
- Research article IgG4-related orbital disease: a meta-analysis and review [9]
- Research article Pseudotumor of the orbit. Clinical, pathologic, and radiologic evaluation [10]
References
- Ren J, Yuan Y, Wu Y, Tao X. Differentiation of orbital lymphoma and idiopathic orbital inflammatory pseudotumor: combined diagnostic value of conventional MRI and histogram analysis of ADC maps. . 2018. PMID 29716527 · DOI · PMC5930683
- Fang Y, Shen B, Dai Q, Xie Q, Wu W, Wang M. Orbital inflammatory pseudotumor: new advances in diagnosis, pathogenesis, and treatment. . 2023. PMID 37794419 · DOI · PMC10548690
- Aryasit O, Tiraset N, Preechawai P, Kayasut K, Sanghan N, Sittivarakul W. IgG4-related disease in patients with idiopathic orbital inflammation. . 2021. PMID 34625052 · DOI · PMC8499436
- Gao L, Zhao H, Liang C, Tang H. Successful treatment of anti-neutrophil cytoplasmic antibody-associated inflammatory pseudotumour with rituximab: A case report. . 2025. PMID 41054076 · DOI · PMC12499677
- Mombaerts I, Goldschmeding R, Schlingemann RO, Koornneef L. What is orbital pseudotumor?. Surv Ophthalmol. 1996. PMID 8827931 · DOI
- Goto H, Takahira M, Azumi A, Japanese Study Group for IgG4-Related Ophthalmic Disease. Diagnostic criteria for IgG4-related ophthalmic disease. Jpn J Ophthalmol. 2015. PMID 25392273 · DOI
- Jacobs D, Galetta S. Diagnosis and management of orbital pseudotumor. Curr Opin Ophthalmol. 2002. PMID 12441835 · DOI
- Wallace ZS, Khosroshahi A, Jakobiec FA, Deshpande V, Hatton MP, Ritter J, et al.. IgG4-related systemic disease as a cause of "idiopathic" orbital inflammation, including orbital myositis, and trigeminal nerve involvement. Surv Ophthalmol. 2012. PMID 22018678 · DOI
- Andrew N, Kearney D, Selva D. IgG4-related orbital disease: a meta-analysis and review. Acta Ophthalmol. 2013. PMID 22963447 · DOI
- Weber AL, Romo LV, Sabates NR. Pseudotumor of the orbit. Clinical, pathologic, and radiologic evaluation. Radiol Clin North Am. 1999. PMID 10026735 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-11-04; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-11-04.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.